

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NOS.: See attached Schedule A

ASSIGNEE: TargeGen, Inc.

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST**  
**REVOCATION OF PRIOR POWERS AND NEW POWER OF ATTORNEY**

Sir:


As an authorized representative of the assignee of record of the entire right, title, and interest in the patent applications identified in the attached Schedule A, I hereby revoke all powers of attorney previously given and hereby appoint the registered patent practitioners associated with **Customer Number 051414** to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith.

Please direct all correspondence for the above-identified patent applications to the address associated with the above Customer Number.

The assignee of record of the entire right, title, and interest in the above-identified patent applications is **TargeGen, Inc.** by virtue of the chain of title from the inventors of the above-identified patent applications to the current assignee.

Respectfully submitted,

Dated: September 6, 2007

  
\_\_\_\_\_  
Peter G. Ulrich, President and CEO  
TargeGen, Inc.  
9380 Judicial Drive  
San Diego, California 92121  
United States of America

**Schedule A**

Application No./Patent No.	Filing Date	Title	Attorney Docket No./Former Attorney Docket No.	Reel and Frame Number
7,208,493	10/02/03	Vasculostatic Agents and Methods of Use Thereof	TRG-111/TARG-1110-3	014666/0766
11/653,190	01/11/07	Vasculostatic Agents and Methods of Use Thereof	TRG-111C1/TARG-1110-5	014666/0766
11/105,845	04/13/05	Vasculostatic Agents and Methods of Use Thereof	TRG-111CP/TARG-1110-4	016023/0024
60/415,981	10/03/02	SRC Inhibitors and Methods for Use Thereof	TRG-111P1/TARG-1110	103586/0793
60/440,234	01/14/03	SRC Inhibitors and Methods for Use Thereof	TRG-111P2/TARG-1110-1	013776/0484
60/479,295	06/17/03	Vascular Permeability Inhibitors and Methods for Use Thereof	TRG-111P3/TARG-1110-2	014458/0427
11/102,405	04/07/05	Benzotriazine Inhibitors of Kinases	TRG-116/TARG-1160-2	016424/0283
60/561,237	04/08/04	Benzotriazine Inhibitors of Kinases	TRG-116P1/TARG-1160	016467/0841
60/643,439	01/12/05	Benzotriazine Inhibitors of Kinases	TRG-116P2/TARG-1160-1	016467-0864
11/212,064	08/24/05	Heterocyclic Compounds and Methods of Use	TRG-121/TARG-1210-2	019411/0368
60/604,298	08/25/04	Heterocyclic Compounds and Methods of Use	TRG-121P1/TARG-1210	01941/0301
60/696,168	07/01/05	Heterocyclic Compounds and Methods of Use	TRG-121P2/TARG-1210-1	019411/0334
11/377,234	03/15/06	Pyrimidine Inhibitors of Kinases	TRG-123-1/TARG-1230-1	018049/0517

Application No./Patent No.	Filing Date	Title	Attorney Docket No./Former Attorney Docket No.	Reel and Frame Number
11/449,219	06/07/06	Methods and Compositions for the Treatment of Ocular Disorders	TRG-124/TARG-1240-3	018610/0877
60/689,111	06/08/05	Methods and Compositions for the Delivery of Lipophilic Drugs	TRG-124P1/TARG-1240	016467/0847
60/763,537	01/30/06	Methods and Compositions for the Delivery of Lipophilic Drugs	TRG-124P2/TARG-1240-1	018610/0877
11/588,638	10/26/06	Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases	TRG-125/TARG-1250-2	018791/0911
11/796,717	04/26/07	Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases	TRG-125CP/TARG-1250-3	019600/0122
60/732,629	11/01/05	Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases	TRG-125P1/TARG-1250	018916/0540
60/838,003	08/15/06	Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases	TRG-125P2/TARG-1250-1	018782/0239
11/591,076	10/31/06	Inhibitors Targeting Resistant Kinase	TRG-126A/TARG-1260A-1	018964/0673
11/591,252	10/31/06	Thiazole Inhibitors Targeting Resistant Kinase Mutations	TRG-126B/TARG-1260-2	018964/0732
11/772,572	07/02/07	2-Amino-5-Substituted Pyrimidine Inhibitors	TRG-127/TARG-1270-1	019774/0567
11/789,832	04/25/07	Kinase Inhibitors and Methods of Use Thereof	TRG-128/TARG-1280-1	019600/0230